Menu
Menu
Virtual Investor Event
To discuss the current spinal cord injury treatment landscape and
NervGen’s Phase 1b/2a trial evaluating NVG-291 in spinal cord injury
April 9, 2025 | 10:00am EDT
Click here to register and attend the event
Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 11, 2025 | 8:40am EST
Click here to listen to the fireside chat
Virtual Life Sciences Investor Forum
Hosted by OTC Markets Group and VirtualInvestorConferences.com
March 13, 2025 | 12:00pm EDT
Click here to listen to the presentation
Webinar Panel Discussion:
Clinical Research Advancements in Spinal Cord Injury (SCI)
September 5, 2024 | 5:00pm EDT
Click here to listen to the webinar
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com
